How Betahistine Works

Serc, the brand name for betahistine, is a histamine analogue that is widely used in the treatment of vertigo and balance disorders, particularly those associated with Ménière's disease. Its principal action is believed to involve improvement of blood flow within the inner ear and modulation of histamine receptors in the vestibular system. Betahistine is generally considered a medication for peripheral vestibular disorders rather than for conditions of the central nervous system.

Clinicians prescribe betahistine to reduce the frequency and intensity of vertigo attacks, often as part of a longer-term treatment plan. While it may provide symptomatic relief, the response varies among individuals, and it is not considered effective for all forms of dizziness.

Central Vestibular Disorders and Red Flags

When balance symptoms arise from the brainstem, cerebellum, or other central structures, they require a different diagnostic approach. Conditions such as vestibular migraine, central paroxysmal positional vertigo, or brainstem dysfunction may not respond well to betahistine. Clinicians must distinguish between peripheral and central causes of vertigo because the treatment strategy differs substantially.

In some central disorders, other oral agents have a clearer evidence base. These include baclofen, a muscle relaxant sometimes used for downbeat nystagmus or paroxysmal symptoms; gabapentin, an anticonvulsant that can help reduce certain forms of central nystagmus; and benzodiazepines, such as diazepam or clonazepam, which act as vestibular suppressants and are occasionally used for short-term symptomatic treatment of anxiety-related dizziness or acute vertigo.

Carbonic Anhydrase Inhibitors in Vestibular Care

A distinct class of drugs, the carbonic anhydrase inhibitors, works by altering fluid and ion balance in the inner ear and central nervous system. Acetazolamide is the most commonly encountered carbonic anhydrase inhibitor in vestibular medicine. It may be used in some cases of Ménière's disease and is also relevant in inherited episodic ataxia syndromes, including episodic ataxia type 2, where it can reduce the frequency of attacks. The role of carbonic anhydrase inhibitors is therefore distinct from that of betahistine, baclofen, gabapentin, and benzodiazepines.

Choosing Among Treatment Options

The selection of therapy depends on the presumed site of pathology, the clinical pattern, and coexisting medical factors. A basic overview of this clinical decision-making includes the following:

• Betahistine is often tried first in typical Ménière's disease or recurrent peripheral vestibular vertigo.
• Baclofen may be considered in specific central eye movement disorders with oscillopsia, though its use is less common.
• Gabapentin is sometimes used off-label for persistent central symptoms, particularly nystagmus or vestibular paroxysmia.
• Benzodiazepines may provide rapid but temporary suppression of acute dizziness; however, their chronic use is limited by sedation, tolerance, and dependency.
• Carbonic anhydrase inhibitors such as acetazolamide are used in selected patients with Ménière's disease and are first-line in certain episodic ataxias.

Because central vestibular syndromes often require careful investigation and a multidisciplinary approach, most guidelines recommend referral to a specialised balance clinic when symptoms are atypical or do not improve with initial treatment. The evidence supporting betahistine for central vestibular disease remains limited, and clinicians should not rely on it alone when a disorder such as vestibular migraine or central paroxysmal vertigo is suspected.

In practice, the use of baclofen, gabapentin, benzodiazepines, and carbonic anhydrase inhibitors is best guided by pharmacological knowledge and clinical experience. Vestibular rehabilitation therapy is frequently combined with these medications to promote central compensation and improve functional recovery.

Conclusion

Betahistine holds a well-established place in the peripheral vestibular treatment pathway, particularly for Ménière's disease. Its value in central vestibular disorders is less certain, and there the clinician may turn to baclofen, gabapentin, benzodiazepines, or carbonic anhydrase inhibitors depending on the specific diagnosis. Each agent acts through a different mechanism, and the choice of treatment should be aligned with the underlying cause of the symptoms, the adverse effect profile of the drug, and the broader goals of patient care.